HAS2 and glioblastoma: A similar scenario involving miRNA species/hPRPS1 transcripts and DLEU1—lnc RNA deleted in lymphocytic leukaemia 1 [230]—or lncRNA HAS2-AS1 (HAS2 (hyaluronan synthase 2) antisense RNA 1) [231], which are found to increase progression in various cancers, e.g., glioblastoma multiforme, suggests a potential therapeutic target for glioblastoma multiforme or CRC by destroying the interaction of miRNA/hPRPS1 mRNA via ‘mopping up’ the miRNA with a concomitant reduction in hPRPS1 activity.